Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The Washington State University neurological drug developer has gone public after issuing 12 million shares priced at $17 each.

Chime has increased its valuation nearly tenfold in 18 months and is worth $14.5bn following a $485m series F round that included existing shareholder Access Industries.

SymBiosis and Susquehanna International Group were among a consortium of new and existing backers that supplied $90m in series D financing to Finch Therapeutics.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

The telehealth system provider is going public in an $742m upsized offering that will enable Philips, Allianz, Teva and Takeda to exit.

OSU's kidney dialysis technology provider has added about $36m to close its initial public offering, its shares having more than doubled in price.

The kidney dialysis technology provider has added about $36m to close its initial public offering, it shares having more than doubled in price.

SR One, AbbVie Ventures, Takeda Ventures and Pfizer Ventures all returned having already backed the cancer and inflammatory disease drug developer at series A stage.

The healthcare-focused workplace management software provider hiked its total funding to about $225m as Ascension Ventures reinvested.